Lupus, rheumatoid arthritis and IBD

One question runs through all of them

Autoimmune conditions cover a wide range, and underwriters look at each one on its own. What they share is one central question: has this affected an organ?

Take a condition that causes joint pain, tiredness and swelling. It is managed with medication. It has not damaged the kidneys, lungs, heart or liver. An underwriter treats that as a long-term condition with a manageable effect on the file. Now take the same diagnosis with organ damage on record. That is a different file. Often it is assessed on the organ rather than on the autoimmune label.

Keep that split in mind through everything below.

Rheumatoid arthritis

This is usually one of the better-assessed conditions in the group.

Underwriters look at how long you have had it and how active it is now. They look at what treatment you need. They also look at whether it has caused damage or disability. Well-controlled RA on stable treatment, with normal function and no complications, is commonly insurable at reasonable terms. Sometimes it gets standard rates.

Attention increases in three cases. One is major joint damage that affects how you function. Another is inflammation markers in the blood that stay high. The third is lung involvement, which happens in a minority of cases and shifts the assessment.

Worth stating clearly: rheumatoid arthritis is an inflammatory autoimmune condition. It is assessed quite differently from osteoarthritis, which comes from wear and is rarely a rating factor at all. Applications sometimes record only “arthritis”. Naming which one you have is worth doing.

Inflammatory bowel disease

Canada has among the highest rates of Crohn’s disease and ulcerative colitis in the world. So underwriters here see this all the time.

Crohn’s disease is assessed on how much of the bowel is affected and how often flares occur. Underwriters ask whether surgery has been needed. They also ask about complications such as fistulas or a blocked bowel. Several bowel resections, meaning surgeries that remove part of the bowel, point to more serious disease.

Ulcerative colitis is assessed on how much of the colon is affected, how often it flares, and whether surgery has been needed. Colitis that is both extensive and longstanding carries a higher risk of colorectal cancer. Underwriters take an interest in whether you are having regular surveillance colonoscopies.

For both, the picture that reads well is this: disease controlled on stable treatment, no recent flares, no hospital stays, weight maintained, and regular follow-up on record.

Someone diagnosed fifteen years ago who has stayed in sustained remission on the same therapy is a straightforward file.

Lupus

Lupus is assessed most cautiously of the group. The reason is organ involvement.

Systemic lupus erythematosus, or SLE, can affect the kidneys, heart, lungs and central nervous system. Where it does, the assessment reflects that organ damage as much as the lupus itself.

Kidney involvement matters most. Lupus nephritis, meaning lupus that has inflamed the kidneys, moves the file a long way. It is assessed alongside the points covered in kidney disease.

The picture is much more favourable where lupus has stayed in the skin and joints, has been stable for a long time, and organ screening has stayed clear. Ratings are common. Declines go with active disease, major organ involvement, or recent flares.

Time and stability carry unusual weight here. Lupus is a relapsing condition, meaning it comes and goes, so a long quiet period is meaningful evidence.

Treatment tells its own story

Underwriters read your treatment as a guide to how severe the disease is. They do the same for other conditions.

Stable long-term therapy on an unchanged regimen reads well. It suggests the condition is under control.

Biologic therapy is common in all three conditions now, and it is not a negative in itself. It does show that first-line treatment was not enough, and underwriters note that. Long-term stability on a biologic is read favourably.

Long-term oral steroids are the item underwriters flag on their own. Steady use of oral corticosteroids over a long period is noted in its own right. That is because of its own effects over time, on top of what it says about disease activity. Short courses for flares are ordinary. Continuous long-term use at higher doses is not.

Frequent treatment changes suggest a condition that has been hard to control.

Hospital admissions and surgery

These are counted, as elsewhere. Admissions for flares, surgery, and any time in intensive care all mark severity. How recent they were matters too.

For IBD, the surgical history is especially telling: what was removed, how many procedures, and whether you have an ostomy.

Applying

Be specific about the diagnosis. “Autoimmune condition” tells an underwriter nothing. The named condition, its extent and its organ involvement tell them everything.

Have these ready: when you were diagnosed, your current treatment and how long you have been on it, any steroid use, any hospital stays or surgery with dates, the results of any organ screening, the date of your last flare, and your specialist’s name.

Apply fully underwritten. These conditions produce a wide spread between insurers. That is especially true for well-controlled disease on biologic therapy, where guidelines have been updating.

If full underwriting does not produce an offer, simplified issue products may be available, depending on their specific questions. Guaranteed issue asks nothing about health, at a smaller amount.

The boundary

This page describes insurance underwriting. It is not information about lupus, rheumatoid arthritis or inflammatory bowel disease. Nothing here is guidance about treatment. Your rheumatologist, gastroenterologist or family doctor owns all of that.